Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rezdiffra
Pharma
Novo Nordisk's semaglutide delivers in phase 3 MASH study
With a positive readout for MASH now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.
Fraiser Kansteiner
Nov 1, 2024 10:38am
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Sep 6, 2024 6:30am
Madrigal tipped to target scientific events to boost MASH growth
Aug 12, 2024 8:15am
Sales strong for Madrigal's Rezdiffra, but shares down 13%
Aug 7, 2024 2:56pm
Lilly pads tirzepatide's MASH win with detailed fibrosis data
Jun 5, 2024 3:04pm
